| Specificity |
This product is specific for Ustekinumab |
| Host Species |
Mouse |
| Immunogen |
Ustekinumab |
| Conjugate |
Unconjugated |
|
Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. |
| Application |
Recommended Usage |
| ELISA |
0.005-1 µg/ml |
| Competitive ELISA |
10-50 µg/ml |
|
| Form |
Lyophilized |
| Storage Buffer |
This product is lyophilized with PBS, pH 7.2, containing 0.02% sodium azide. |
| Reconstitution |
Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/ml. |
| Storage Instructions |
The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles. |
| Purification |
Protein A affinity column |
| Isotype |
Mouse IgG1,κ |
| Clonality |
Monoclonal |
| Clone ID |
11E3 |
| Note |
GenScript can customize this product per customer's request including product size, buffer components, etc. |
Anti-Ustekinumab Antibody (11E3), mAb, Mouse (GenScript, A02119-40) blocks Ustekinumab binding with Human IL-12 recombinant protein.
Coating antigen: IL-12 1 µg/ml.
Ustekinumab final concentration: 6 ng/ml.
Anti-Ustekinumab antibody dilutions start from 30 μg/ml.
IC50= 0.5 µg/ml.
ELISA binding of Anti-Ustekinumab Antibody (11E3), mAb, Mouse (GenScript, A02119-40) with Ustekinumab. While the antibody does not recognize the human IgG (data not shown).
Coating antigen: Ustekinumab, 1 µg/ml.
Anti-Ustekinumab Antibody (11E3), mAb, Mouse (GenScript, A02119-40) dilution start from 1,000 ng/ml.
EC50= 11.14 ng/ml.
| Target Background |
Ustekinumab with trade name Stelara, is an FDA-approved drug to Crohn's disease, Ulcerative Colitis, Plaque Psoriasis and Psoriatic Arthritis, targeting both interleukins (IL)-12 and IL-23. Ustekinumab is a fully human immunoglobulin G1 kappa mAb that binds to IL-12 and IL-23. Ustekinumab binds to the p40 subunit common to IL-12 and IL-23 and prevents their interaction with the IL-12 receptor β1 subunit of the IL-12 and IL-23 receptor complexes, thereby disrupting the proinflammatory pathway.Anti-Ustekinumab Antibody (11E3), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Ustekinumab. |
| Synonyms |
Mouse monoclonal to Ustekinumab/Stelara |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
